About this item:

432 Views | 570 Downloads

Author Notes:

Email Address:jeanne.hendrickson@yale.edu

Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.


Research Funding:

This work was funded in part by NIH/NHLBI (R21 HL11569, R01 HL126076) and by the Emory Egleston Children’s Research Center, to JEH.


  • Cell Therapy and Immunotherapy
  • Red Cells
  • Transfusion Medicine

Anti-KEL Sera Prevents Alloimmunization to Transfused KEL RBCs in a Murine Model.


Journal Title:



Type of Work:

Article | Final Publisher PDF


Alloantibodies against red blood cell (RBC) antigens, which may be generated following exposure to foreign antigens on transfused RBCs or on fetal RBCs during pregnancy, can be clinically significant from the standpoint of morbidity and mortality.1 In the transfusion setting, RBC alloantibodies can lead to premature clearance of transfused RBCs, resulting in hemolytic transfusion reactions and even death in severe cases. In the pregnancy setting, these antibodies can cause hemolytic disease of the fetus and newborn (HDFN). With the exception of RhIg, which is primarily utilized to prevent Rh(D) alloimmunization in pregnancy, no antigen specific targeted therapies exist to prevent RBC alloimmunization.

Copyright information:

© Ferrata Storti Foundation

This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License ( http://creativecommons.org/licenses/by/3.0/), which permits distribution, public display, and publicly performance, distribution of derivative works, making multiple copies, provided the original work is properly cited. This license requires copyright and license notices be kept intact, credit be given to copyright holder and/or author.

Creative Commons License

Export to EndNote